HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Lowers Price Target to $45

Benzinga · 12/02/2025 12:05
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $70 to $45.